# A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

> **NCT04688931** · PHASE3 · TERMINATED · sponsor: **UroGen Pharma Ltd.** · enrollment: 282 (actual)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma
- Urothelial Carcinoma Bladder

## Interventions

- **DRUG:** UGN-102
- **PROCEDURE:** TURBT

## Key facts

- **NCT ID:** NCT04688931
- **Lead sponsor:** UroGen Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-19
- **Primary completion:** 2023-03-17
- **Final completion:** 2023-03-17
- **Target enrollment:** 282 (ACTUAL)
- **Why stopped:** Alternate approach pursued
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04688931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04688931, "A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04688931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*